醫(yī)院動態(tài)
CGGA數(shù)據(jù)庫發(fā)布2000例腦膠質(zhì)瘤組學(xué)數(shù)據(jù) 中國數(shù)據(jù)庫面向全球研究者免費開放
近日,中國腦膠質(zhì)瘤基因組圖譜計劃(CGGA, Chinese Glioma Genome Atlas; http://cgga.org.cn)數(shù)據(jù)庫發(fā)布2000例中國腦膠質(zhì)瘤樣本的功能基因組學(xué)數(shù)據(jù)。經(jīng)過15年的臨床標本和組學(xué)數(shù)據(jù)積累,目前該數(shù)據(jù)庫日臻完善,全部基因組數(shù)據(jù)向全世界研究者免費開放。據(jù)不完全統(tǒng)計,已有美國、歐洲多家知名研究機構(gòu)近200篇SCI論文引用該數(shù)據(jù)庫。
CGGA發(fā)起人和創(chuàng)建者,北京市神經(jīng)外科研究所副所長、首都醫(yī)科大學(xué)附屬北京天壇醫(yī)院神經(jīng)外科副主任江濤介紹,此次公布的2000例中國腦膠質(zhì)瘤樣本的功能基因組學(xué)數(shù)據(jù),涉及不同組織病理分類、不同WHO惡性度分級、原發(fā)/復(fù)發(fā)配對樣本,功能組學(xué)數(shù)據(jù)涵蓋全外顯測序 (286例)、mRNA芯片(301例)及其測序(1018例)、microRNA芯片(198例)、以及DNA甲基化芯片(159例)。
據(jù)介紹,這個數(shù)據(jù)庫中包含了詳盡的臨床數(shù)據(jù),包括患者性別、年齡、放療和化療情況、完整隨訪數(shù)據(jù)等,針對不同組學(xué)數(shù)據(jù)特點,研究團隊還開發(fā)了不同的在線分析工具,包括腦膠質(zhì)瘤突變圖譜繪制、基因表達及其DNA甲基化的分布模式展示、相關(guān)性分析以及生存分析結(jié)果可視化等。
該數(shù)據(jù)庫的建立有助于描繪中國人群腦膠質(zhì)瘤的基因組及分子遺傳學(xué)特征,探尋腦膠質(zhì)瘤發(fā)生發(fā)展過程中的重要分子機制,為腦膠質(zhì)瘤的分子分型和藥物靶點研發(fā)提供指導(dǎo),并為腦膠質(zhì)瘤精準醫(yī)學(xué)全鏈條的發(fā)展奠定基礎(chǔ)。
“希望通過基因組學(xué)技術(shù)分析,全面繪制中國人群的腦膠質(zhì)瘤基因組圖譜,讓國內(nèi)外更多從事腦膠質(zhì)瘤的研究者可以對數(shù)據(jù)庫進行挖掘利用。”江濤說。
腦膠質(zhì)瘤是成人最常見的顱內(nèi)原發(fā)惡性腫瘤。2004年起,江濤開始致力于中國腦膠質(zhì)瘤生物樣本庫的建立及臨床隨訪數(shù)據(jù)的收集。在我國神經(jīng)外科創(chuàng)始人王忠誠院士的指導(dǎo)下,2012年江濤團隊啟動CGGA。
依托于國家神經(jīng)系統(tǒng)疾病臨床醫(yī)學(xué)研究中心、北京市神經(jīng)外科研究所,以及首都醫(yī)科大學(xué)附屬北京天壇醫(yī)院,目前CGGA數(shù)據(jù)庫已經(jīng)成為亞洲乃至全世界最大規(guī)模的腦膠質(zhì)瘤醫(yī)學(xué)信息工程。江濤表示,不斷建設(shè)和完善的CGGA數(shù)據(jù)庫,將對促進我國腦膠質(zhì)瘤領(lǐng)域基礎(chǔ)和臨床研究水平的發(fā)展并提高我國癌癥研究的國際影響力,最終推動腦膠質(zhì)瘤新型診療模式的發(fā)展,讓更多腦膠質(zhì)瘤患者獲益起到積極作用。
CGGA數(shù)據(jù)庫代表性文章產(chǎn)出:
1.Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, QianZ, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T.Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in BrainTumor. Cell. 2018 Nov 29;175(6):1665-1678.e18.
2.Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, Ramakrishnan V, Li J, Carter B, Liu YW, Hu HM, Wang Z, Li MY, Yao K, Qiu XG, Kang CS, You YP, Fan XL, Song WS, Li RQ, Su XD, Chen CC, Jiang T. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014 Nov;24(11):1765-73.
3.Zhang Y, Li J, Yi K, Feng J, Cong Z, Wang Z, Wei Y, Wu F, Cheng W, Samo AA, Salomoni P, Yang Q, Huang Y, Kang C, Jiang T, Fan X. Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6975-6984.
4.Shan X, Fan X, Liu X, Zhao Z, Wang Y, Jiang T. Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis. Neuro Oncol. 2018 Feb 19;20(3):324-331.
5.Wang Z, Hao Y, Zhang C, Wang Z, Liu X, Li G, Sun L, Liang J, Luo J, Zhou D, Chen R, Jiang T. The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. Clin Cancer Res. 2017 May 1;23(9):2177-2185.
6.Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016 Aug;18(8):1099-108.
7.Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A. Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017 Oct 15;23(20):6279-6291.
8.Sun Y, Zhang W, Chen D, Lv Y, Zheng J, Lilljebj?rn H, Ran L, Bao Z, Soneson C, Sj?gren HO, Salford LG, Ji J, French PJ, Fioretos T, Jiang T, Fan X. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3538-43.
9.Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012 Dec;14(12):1432-40.
10.Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012 Jun;14(6):712-9.
(北京市神經(jīng)外科研究所 分子神經(jīng)病理研究室 趙征)